Analysis of clinical characteristics and efficacy of chronic myeloid leukemia onset with extreme thrombocytosis in the era of tyrosine kinase inhibitors

Figures & data

Table 1 Clinical characteristics of patients in CML-T group and CML-N group

	CML-T group (n=22)	CML-N group (n=65)	P-value
Gender			0.022
Male	45.5% (10/22)	72.3% (47/65)
Female	54.5% (12/22)	27.7% (18/65)
Age			0.321
>60 y	18.2% (4/22)	7.7% (5/65)
≤60 y	81.8% (18/22)	92.3% (60/65)
WBC (×10^9/L)			0.730
Median	106.0	170.0
Range	8.9–453.0	2.8–474.0
HGB (g/L)			0.106
Median	101	105
Range	59–144	61–166
PLT (×10^9/L)			0.000
Median	1,398	326
Range	1,038–3,649	112–737
Spleen (cm)			0.745
Median	5.2	5.5
Range	0–18.0	0–18.0

Note: Significant differences between the two groups groups for these factors are shown in bold.

Abbreviations: CML, chronic myeloid leukemia; CML-T, CML with thrombocytosis; CML-N, CML without extreme thrombocytosis; y, years; WBC, white blood cell; HGB, hemoglobin; PLT, platelet.

Table 2 The parameters of PB and BM smear

	CML-T group	CML-N group	P-value
EO% in PB			0.100
Median	5.0	3.2
Range	0–23.0	0–18.0
BA% in PB			0.779
Median	2.8	2.4
Range	0–13.0	0–11.0
Blast% in PB			0.168
Median	1.2	0.7
Range	0–7.0	0–8.0
Megakaryocytes in BM			0.047
>100	7	7
≤100	15	58

Note: Significant differences between the two groups groups for these factors are shown in bold.

Abbreviations: PB, peripheral blood; BM, bone marrow; CML, chronic myeloid leukemia; CML-T, CML with thrombocytosis; CML-N, CML without extreme thrombocytosis; EO, eosinophils; BA, basophils.

Table 3 Sokal, Hasford and EUTOS score of patients in CML-T group and CML-N group

	CML-T group (n=22)	CML-N group (n=65)	P-value
Sokal score			0.000
Low/intermediate	4.5% (1/22)	47.7% (31/65)
High	95.5% (21/22)	52.3% (34/65)
Hasford score			0.031
Low/intermediate	31.8% (7/22)	58.5% (38/65)
High	68.2% (15/22)	41.5% (27/65)
EUTOS score			0.213
Low	72.7% (16/22)	84.6% (55/65)
High	27.3% (6/22)	15.4% (10/65)

Note: Significant differences between the two groups groups for these factors are shown in bold.

Abbreviations: CML, chronic myeloid leukemia; CML-T, CML with thrombocytosis; CML-N, CML without extreme thrombocytosis; EUTOS, European Treatment and Outcome Study.

Table 4 The percent of MMR in CML-T group and CML-N group

MMR	CML-T group (n=22)	CML-N group (n=65)	P-value
3 months	2 (9.1%)	14 (21.5%)	0.325
6 months	4 (18.2%)	19 (29.2%)	0.310
12 months	6 (27.3%)	25 (38.5%)	0.344
36 months	9 (40.9%)	43 (66.2%)	0.037

Note: Significant differences between the two groups groups for these factors are shown in bold.

Abbreviations: MMR, major molecular response; CML, chronic myeloid leukemia; CML-T, CML with thrombocytosis; CML-N, CML without extreme thrombocytosis.

Figure 1 The median EFS of patients in CML-T group and CML-N group.

Notes: The median EFS of patients in CML-T group was 21 months; however, the median EFS of patients in CML-N group was not reached (P<0.05).
Abbreviations: EFS, event-free survival; CML, chronic myeloid leukemia; CML-T, CML with thrombocytosis; CML-N, CML without extreme thrombocytosis.